Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Combating Generics 2008: Counter-Generics Strategy, Tactics and Execution Cutting Edge Information, Nov 2007, Pages: 159   Description     Table of Contents     Companies Mentioned        Enquire before Buying    Send to a Friend   Protect brand revenues with a multi-tiered counter-generics strategy: Generic drugs now account for more than 60% of all prescriptions filled in the US, and more than $60 billion worth of drugs face US patent expiration by 2011. Use this report to build a counter-generics strategy that includes long-term, R&D-based lifecycle planning (such as new formulations and next-generation drugs) as well as frontline tactics (such as litigation and counter-promotion) -- and understand how companies launch authorized generics and attempt OTC switches Explore primary data for a comprehensive look at current counter-generics defense: - Investigate strategies, investments and results for seven brands - Benchmark your efforts against timelines, investment levels, and past-and-future use of critical lifecycle management and counter-generics options: New formulation launches Defensive pricing changes Counter-promotion Approval for new indications Next-generation product launches Patent litigation Authorized generics negotiations Launches through generics subsidiaries Pediatric trials and six-month exclusivity OTC switching - Compare headcounts dedicated to counter-generics preparation over the life of a brand Metrics Introduction Combating Generics 2008: Counter-Generics Strategy, Tactics and Execution contains more than 450 metrics and 60 charts and graphics. Included among the metrics and charts are: - Counter-generics investments, tactics and results for seven blinded brands - Survey data detailing implementation timelines, investment levels, recent use and planned future use for the following options: - Launch of new formulations - Use of pricing to maintain competitiveness - Counter-promotion in anticipation of generics - Approval for new indications - Next-generation product launches - Patent litigation and citizen petitions - Authorized generics negotations - Launches through generics subsidiaries - Pediatric exclusivity - Rx-to-OTC switching - Counter-generics staffing headcounts by lifecycle stage - Functional involvement in counter-generics and lifecycle planning - Comparisons of trends between new counter-generics data and data collected in past surveys - Sales data for and analysis of steps taken by high-profile drugs facing generic competition Product samples Combating Generics 2008 - Counter-Generics Strategy Tactics and Execution - Chapter 1 Customers who bought this item also bought Combating Generics 2008: Counter-Generics Strategy, Tactics and Execution Actavis Generics Company Intelligence Report Opportunities and Challenges for Generic Drugs in the UK 2007 Impact of Generics on the Antidepressant Market An Exploration of Consolidation in the Generics Industry Authorized Generics: Look Before you Leap Pricing and Reimbursement Issues for Generics and Biosimilars Front-End Strategies to Meet Generics Challenges and Reduce Pharmaceutical Risk

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster